World’s first autoinjector with fully integrated connectivity

Press Releases Ypsomed Group

Burgdorf – Ypsomed has introduced the world’s first autoinjector for prefilled syringes with integrated connectivity. The YpsoMate On combines the advantages of the proven YpsoMate autoinjector with the options of digital therapy support. The YpsoMate On follows an eco-design principle which allows easy recycling of electronic components and encourages the use of sustainable components.

Press Releases Ypsomed Group

Burgdorf – Ypsomed has expanded the range of features of the mylife YpsoPump insulin pump system. New - the app-based integration of the Dexcom G6 Continuous Glucose Monitoring (CGM) System enables people with diabetes to continuously manage their therapy via their smartphone. Users of the mylife YpsoPump receive the advanced function of the pump system – called “mylife Assist” – via an update to the mylife App. The first countries launching mylife Assist are Germany, Switzerland, Austria and Denmark, with further countries following soon.

Press Releases Ypsomed Group

Burgdorf – The Annual General Meeting of the Ypsomed Group on 30 June 2021 approved all proposals of the Board of Directors. The AGM elected Ms Betül Susamis Unaran as a new member of the Board of Directors and authorised the Board to increase the share capital.

Alliance to Zero founded to achieve net zero emissions across the pharmaceutical supply chain

Press Releases Ypsomed Group

Burgdorf – Today, eight companies representing the pharmaceutical supply chain for pharma products announced the founding of the Alliance to Zero, a non-profit membership association for pharma and biotech supply chain companies that aims to facilitate the transition of the pharma sector to compliance with net zero emissions in line with the goals of the Paris Climate Agreement.

Ypsomed continues to invest in growth

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SWX: YPSN) increased its consolidated sales by CHF 9.4 million to CHF 403.7 million in the financial year 2020/21 (prior year: CHF 394.3 million). The two business segments developed differently during the Corona pandemic: while the business with pens and autoinjectors was encouraging, the sales of insulin pumps remained at a low level. Ypsomed has set an important course in the financial year 2020/21 to improve the sales opportunities for YpsoPump. The increased importance of self-treatment of chronic diseases has reinforced the company’s growth strategy. Ypsomed has therefore advanced all strategic initiatives and further improved its own competitive position. The company invested a total of CHF 142.7 million for this purpose while at the same time creating 110 new jobs. To expand financial flexibility for the future, the Board of Directors will propose an authorised increase in capital at the Annual General Meeting.